-
Canaccord Starts Seer Inc. (SEER) at Buy
-
Seer board rejects $2.35 per share buyout offer from Radoff-JEC group
-
Seer receives $2.25 per share acquisition proposal from Radoff-JEC Group
-
PreOmics and Biognosys win US patent challenge against Seer patent
-
SEER wins patent challenge from Bruker subsidiaries
-
Radoff-JEC group calls for SEER sale amid governance concerns
-
Seer, Inc. (SEER) Tops Q4 EPS by 2c
-
The Radoff-JEC Group Issues Open Letter to Seer Inc.’s Board Concerning Immediate Need for Significant Change
-
Seer showcases proteomics technology at US HUPO conference
-
SEER study published in Nature Genetics validates protein analysis platform
-
Seer, Inc. (SEER) Misses Q3 EPS by 1c
-
Seer to present proteomics research at genetics conference
-
Seer, Inc. (SEER) Tops Q2 EPS by 3c
-
Seer, Inc. (SEER) Launches New Proteograph Workflow
-
Seer, Inc. (SEER) Tops Q1 EPS by 3c
-
TD Cowen: 'Top 10 Themes Coming Out of 45th Annual Health Care Conference'
-
Seer, Inc. (SEER) Reports In-Line Q4 EPS
-
TD Cowen: 'Assessing Impact of US Ban on China Exports for LCMS & Flow Cyt Instruments'
-
Seer, Inc. (SEER) Misses Q3 EPS by 4c
-
Seer, Inc. (SEER) Appoints Nicolas Roelofs to its Board
-
Seer, Inc. (SEER) Announces Resignation of Chief Legal Officer
-
Seer (SEER) Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discover

